Business Description
Abbott Laboratories
NAICS : 339112
SIC : 3841
Compare
Compare
Traded in other countries / regions
ABT.USAABT.Canada0Q15.UKABT.ArgentinaABL.GermanyABTT34.BrazilABT.Mexico1ABT.ItalyABT.AustriaABT.PeruABT_KZ.KazakhstanABL.BulgariaABT.SwitzerlandABT.Chile IPO Date
2021-11-12Description
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.21 |
N/A
|
N/A
| |||
Equity-to-Asset | 0.47 |
N/A
|
N/A
| |||
Debt-to-Equity | 0.65 |
N/A
|
N/A
| |||
Debt-to-EBITDA | 3.16 |
N/A
|
N/A
| |||
Interest Coverage | 12.08 |
N/A
|
N/A
| |||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 3.24 | |||||
Beneish M-Score | -2.57 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.8 | |||||
3-Year EBITDA Growth Rate | 0.2 |
N/A
|
N/A
| |||
3-Year EPS without NRI Growth Rate | -1.2 |
N/A
|
N/A
| |||
3-Year FCF Growth Rate | -1.5 |
N/A
|
N/A
| |||
3-Year Book Growth Rate | 12.4 |
N/A
|
N/A
| |||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 9.36 |
N/A
|
N/A
| |||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.65 |
N/A
|
N/A
|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 63.19 |
N/A
|
N/A
| |||
9-Day RSI | 60.11 |
N/A
|
N/A
| |||
14-Day RSI | 57.84 |
N/A
|
N/A
| |||
3-1 Month Momentum % | -22.21 |
N/A
|
N/A
| |||
6-1 Month Momentum % | -25.67 |
N/A
|
N/A
| |||
12-1 Month Momentum % | -4.43 |
N/A
|
N/A
|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.39 |
N/A
|
N/A
| |||
Quick Ratio | 1.01 |
N/A
|
N/A
| |||
Cash Ratio | 0.4 |
N/A
|
N/A
| |||
Days Inventory | 122 |
N/A
|
N/A
| |||
Days Sales Outstanding | 62.02 |
N/A
|
N/A
| |||
Days Payable | 77.88 |
N/A
|
N/A
|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.25 |
N/A
|
N/A
| |||
Dividend Payout Ratio | 0.46 |
N/A
|
N/A
| |||
3-Year Dividend Growth Rate | 7.9 |
N/A
|
N/A
| |||
Forward Dividend Yield % | 2.29 |
N/A
|
N/A
| |||
5-Year Yield-on-Cost % | 3.53 |
N/A
|
N/A
| |||
Shareholder Yield % | 0.58 |
N/A
|
N/A
|
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 56.61 |
N/A
|
N/A
| |||
Operating Margin % | 15.77 |
N/A
|
N/A
| |||
Net Margin % | 11.65 |
N/A
|
N/A
| |||
EBITDA Margin % | 23.15 |
N/A
|
N/A
| |||
FCF Margin % | 15.84 |
N/A
|
N/A
| |||
OCF Margin % | 20.32 |
N/A
|
N/A
| |||
ROE % | 10.66 |
N/A
|
N/A
| |||
ROA % | 6.07 |
N/A
|
N/A
| |||
ROIC % | 7.74 |
N/A
|
N/A
| |||
3-Year ROIIC % | -6.03 |
N/A
|
N/A
| |||
ROC (Joel Greenblatt) % | 62.19 |
N/A
|
N/A
| |||
ROCE % | 10.95 |
N/A
|
N/A
| |||
Years of Profitability over Past 10-Year | 10 |
N/A
|
N/A
| |||
Moat Score | 8 |
N/A
|
N/A
| |||
Tariff Resilience Score | 9 |
N/A
|
N/A
|
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 33.35 |
N/A
|
N/A
| |||
Forward PE Ratio | 19.95 |
N/A
|
N/A
| |||
PE Ratio without NRI | 19.59 |
N/A
|
N/A
| |||
Price-to-Owner-Earnings | 26.3 |
N/A
|
N/A
| |||
PEG Ratio | 5.6 |
N/A
|
N/A
| |||
PS Ratio | 3.86 |
N/A
|
N/A
| |||
PB Ratio | 3.45 |
N/A
|
N/A
| |||
Price-to-Free-Cash-Flow | 24.42 |
N/A
|
N/A
| |||
Price-to-Operating-Cash-Flow | 19.03 |
N/A
|
N/A
| |||
EV-to-EBIT | 25.48 |
N/A
|
N/A
| |||
EV-to-Forward-EBIT | 20.92 |
N/A
|
N/A
| |||
EV-to-EBITDA | 19.19 |
N/A
|
N/A
| |||
EV-to-Forward-EBITDA | 15.53 |
N/A
|
N/A
| |||
EV-to-Revenue | 4.44 |
N/A
|
N/A
| |||
EV-to-Forward-Revenue | 4.1 |
N/A
|
N/A
| |||
EV-to-FCF | 28.04 |
N/A
|
N/A
| |||
Price-to-GF-Value | 0.67 |
N/A
|
N/A
| |||
Price-to-Projected-FCF | 1.69 |
N/A
|
N/A
| |||
Price-to-DCF (Earnings Based) | 1.17 |
N/A
|
N/A
| |||
Price-to-DCF (FCF Based) | 1.47 |
N/A
|
N/A
| |||
Price-to-Median-PS-Value | 0.87 |
N/A
|
N/A
| |||
Earnings Yield (Greenblatt) % | 3.92 |
N/A
|
N/A
| |||
FCF Yield % | 4.11 |
N/A
|
N/A
| |||
Forward Rate of Return (Yacktman) % | 2.91 |
N/A
|
N/A
|
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Abbott Laboratories Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 46,585 | ||
| EPS (TTM) ($) | 3.09 | ||
| Beta | N/A | ||
| 3-Year Sharpe Ratio | -0.24 | ||
| 3-Year Sortino Ratio | -0.35 | ||
| Volatility % | 36.6 | ||
| 14-Day RSI | 57.84 | ||
| 14-Day ATR ($) | 4.29 | ||
| 20-Day SMA ($) | 99.47 | ||
| 12-1 Month Momentum % | -4.43 | ||
| 52-Week Range ($) | 90 - 144.1 | ||
| Shares Outstanding (Mil) | 1,741.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Abbott Laboratories Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Abbott Laboratories Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-01-22 09:00 | In 180 days | ||
| Fourth quarter earnings results for 2026 | 2027-01-22 | In 179 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-15 09:00 | In 81 days | ||
| Third quarter earnings results for 2026 | 2026-10-15 | In 80 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-16 09:00 | 90.02 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-07-16 | 90.02 (+0.00%) | ||
| USD 0.630000 Cash Dividend | 2026-07-15 | 90.02 (+0.00%) | ||
| General meeting for 2026 | 2026-04-24 08:00 | 129.00 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-04-16 09:00 | 129.00 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-16 | 129.00 (+0.00%) |
Show
Entries
Abbott Laboratories Frequently Asked Questions
What is Abbott Laboratories(XKAZ:ABT_KZ)'s stock price today?
The current price of XKAZ:ABT_KZ is $110.00. The 52 week high of XKAZ:ABT_KZ is $144.10 and 52 week low is $90.00.
When is next earnings date of Abbott Laboratories(XKAZ:ABT_KZ)?
The next earnings date of Abbott Laboratories(XKAZ:ABT_KZ) is 2026-10-15 Est..
Does Abbott Laboratories(XKAZ:ABT_KZ) pay dividends? If so, how much?
The Dividend Yield %  of Abbott Laboratories(XKAZ:ABT_KZ) is 2.25% (As of Today), Highest Dividend Payout Ratio of Abbott Laboratories(XKAZ:ABT_KZ) was 0.47. The lowest was 0.35. And the median was 0.41. The  Forward Dividend Yield % of Abbott Laboratories(XKAZ:ABT_KZ) is 2.29%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Abbott Laboratories
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers